je.st
news
Tag: muscular
Sarepta Therapeutics Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2015-07-01 08:07:56| drugdiscoveryonline Home Page
Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, recently announced the completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for eteplirsen on June 26, 2015
Tags: to
treatment
submission
fda
Houston Farmer Directs Funds to Muscular Dystrophy Association
2015-03-24 01:00:24| Chemicals - Topix.net
The Muscular Dystrophy Association has received a $2,500 donation from Houston County farmer Scott Calloway and America's Farmers Grow Communities, sponsored by the Monsanto Fund. The donation will help the organization provide comprehensive health care services to MDA families in their community, through clinical visits and summer camps.
Tags: association
funds
houston
farmer
PTC Therapeutics Begins Rolling NDA Submission To The FDA For Translarna To Treat Duchenne Muscular Dystrophy
2014-12-29 01:59:52| drugdiscoveryonline Home Page
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)
Tags: treat
begins
rolling
submission
'CureDuchenne Ventures' Launched To Accelerate Drug Discovery And Development For Duchenne Muscular Dystrophy
2013-10-02 05:57:32| drugdiscoveryonline News Articles
CureDuchenne announced today the launch of CureDuchenne Ventures, a new initiative to identify and develop a robust pipeline of therapies to treat Duchenne, the most common and lethal form of muscular dystrophy
Tags: development
drug
discovery
launched
GSK, Prosensa muscular dystrophy drug misses study goal
2013-09-20 17:19:30| Biotech - Topix.net
An experimental drug for Duchenne muscular dystrophy from GlaxoSmithKline and Prosensa failed to meet its goal in a late-stage clinical trial, sending shares in Prosensa tumbling 75 percent in pre-market trade.
Tags: study
goal
drug
muscular